Tony, Have you done any estimates on what Perseis is worth if these trials are a success... MAB's have a success rate of about 50% higher than any other drug class from memory.
I have been watching the excitement over at PAB which is trialling Polyclonal Antibodies. Which are a lot mor expensive to manufacture.. Unless this has been over come recently.
But the space is still very hot.....
Maybe NEU would farm this project out...An upfront would come in very handy for continued work in the Neurospace.
exceptional volumes, page-19
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.57 |
Change
2.170(15.1%) |
Mkt cap ! $2.117B | |||
| Open | High | Low | Value | Volume |
| $14.85 | $16.67 | $14.60 | $24.77M | 1.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.57 | 1717 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |